In vitro antileishmanial properties of tri- and pentavalent antimonial preparations
نویسندگان
چکیده
منابع مشابه
The pentavalent antimonial therapy
Sharon Rose Aragão Macedo , Larissa Deadame de Figueiredo Nicolete , Amália dos Santos Ferreira , Neuza Biguinati de Barros , Roberto Nicolete ⁎ a Laboratório de Biotecnologia Aplicada à Saúde, Fundação Oswaldo Cruz (Fiocruz Rondônia), BR-364, Km 3,5, 76812-245 Porto Velho, RO, Brazil b Programa de Pós-Graduação em Biologia Experimental (PGBioexp), Universidade Federal de Rondônia, BR-364, Km 9...
متن کامل[Premature birth after the use of pentavalent antimonial: case report].
A case is reported of a 19-year-old woman, at week 24 of gestation, with visceral leishmaniosis. She was treated with meglumine antimoniate at a dose of 850 mg/day for 20 days. There occurred premature birth on day five of treatment and the neonate died one day after birth. Considering the importance of protozoiasis in our population and the rarity of the association with pregnancy, we resolved...
متن کامل[A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use].
The authors report a case of mucocutaneous leishmaniasis in a 45-year-old patient who was unsuccessfully treated with pentavalent antimonial for 30 days. After 10 days from the initial treatment and before starting a new therapeutic regimen with the same drug the patient died due to sudden cardiac arrest.
متن کاملIn Vitro Antileishmanial Properties of Neutron-Irradiated Meglumine Antimoniate
Pentavalent antimony, as meglumine antimoniate (Glucantime) or sodium stibogluconate (Pentostam), is the main treatment for leishmaniasis, a complex of diseases caused by the protozoan Leishmania, and an endemic and neglected threat in Brazil. Despite over half a century of clinical use, their mechanism of action, toxicity and pharmacokinetic data remain unknown. The analytical methods for de...
متن کاملClinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.
BACKGROUND Treatment for cutaneous leishmaniasis (CL) with standard pentavalent antimonial therapy is hampered by cumbersome administration, toxicity, and potential failure. Knowledge of factors influencing treatment outcome is essential for successful management. METHODS A case-control study of incident cases was performed with patients experiencing their first CL episode. The standard treat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Antimicrobial Agents and Chemotherapy
سال: 1995
ISSN: 0066-4804,1098-6596
DOI: 10.1128/aac.39.6.1234